Aardvark Therapeutics GAAP EPS of -$0.88
at seekingalpha.com (Fri, 13-Nov 8:47 AM)
AARD rises as a shareholder investigation spotlights ARD-101 safety claims tied to the February 2025 IPO
Market Chameleon (Tue, 27-Oct 10:28 AM)
Aardvark Therapeutics rises as a shareholder investigation spotlights ARD-101 safety claims and trial setbacks
Market Chameleon (Wed, 21-Oct 10:33 AM)
AARD lawsuit notice spotlights ARD-101 trial pause and FDA clinical hold, with an Oct. 13, 2026 lead-plaintiff deadline
Market Chameleon (Wed, 7-Oct 10:48 AM)
Robbins LLP investigation spotlights ARD-101 trial pause and FDA clinical hold at Aardvark Therapeutics (AARD)
Market Chameleon (Fri, 18-Sep 11:02 AM)
